EUSA Pharma - Articles and news items

MAA submitted for tivozanib for the treatment of RCC

Industry news / 1 March 2016 / Victoria White

Tivozanib is an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI)…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+